FULC Q2 2020 Earnings — Fulcrum Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

FULCFulcrum Therapeutics, Inc.

$411M

Q2 2020 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$2M

Gross Profit

-$11M-538.8% margin

Operating Income

-$16M-796.2% margin

Net Income

-$16M-784.3% margin

EPS (Diluted)

$-0.66

QoQ Revenue Growth

+166.7%

Cash Flow

Operating Cash Flow

-$14M

Free Cash Flow

-$14M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$145M

Total Liabilities

$23M

Stockholders' Equity

$122M

Cash & Equivalents

$76M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$2M	$0	—
Gross Profit	-$11M	-$11M	+0.8%
Operating Income	-$16M	-$13M	-18.0%
Net Income	-$16M	-$13M	-19.1%